Jade Biosciences, Inc. (JBIO)
$13.42-4.14%Close
SELLCRISIS · day 28
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $438M
- Beta
- 1.45
- P/E (TTM)
- -4.88
- Short % float
- 49.90%
- Days to cover
- 11.3
- SI change
- +10.3%
- 1W
- +0.07%
- 1M
- -26.18%
- vs SPY 1W
- +0.21%
- vs SPY 1M
- -28.69%
Industry peers
FMP comparable companies · ranked by market cap
- VERASELLVera Therapeutics, Inc.$2.1BCRISISQ 20$29.88-3.35%
- TRAXSELLFirst Tracks Biotherapeutics Inc$1.1BQ 80$31.85-6.96%
- MLTXSELLMoonLake Immunotherapeutics$910MCRISISQ -1$10.82-2.53%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-3.61%
- CTNMSELLContineum Therapeutics, Inc.$503MCRISISQ -6$13.38-1.75%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on JBIO?
- LOPJLB’s latest quantitative signal on Jade Biosciences, Inc. (JBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is JBIO in?
- Jade Biosciences, Inc. (JBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Jade Biosciences, Inc. (JBIO) do?
- Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. …